Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial 3'RNA sequencing was performed in 1,733 ...

Researchers explained that treatment omission or discontinuation in the adjuvant setting was primarily due to postoperative complications and toxicity “but also to patient-related factors, ...